Cardinal Health

Current directors and officers who also hold a role at another S&P 500 company.

• Aaron E. AltKDP · Director
• Akhil JohriBA · Director
• Jason M. HollarDVA · Director
• Nancy KilleferMETA · Director
• Robert W. MusslewhiteCSGP · Director
• Sheri H. EdisonUNP · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Aug 5, 2026

   On August 4, 2026, Cardinal Health, Inc. (the “Company”) appointed Anita Zielinski as its Chief Accounting Officer of the Company, effective November 5, 2026. Ms. Zielinski will succeed Mary Scherer, who will continue to serve as Chief Accounting Officer through November 5, 2026. Ms. Zielinski will join Cardinal as Senior Vice President Finance, effective September 16. Ms. Zielinski, 52, has served as interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller of Baxter International, Inc. (“Baxter”) since March 16, 2026. Ms. Zielinski joined Baxter in February 2025 as Senior Vice President, Chief Accounting Officer and Controller. Prior to joining Baxter, Ms.

   Read the 8-K filing
2. Mar 23, 2026

   On March 17, 2026, Gregory B. Kenny notified Cardinal Health, Inc. (the “Company”) of his decision to retire from the Board of Directors (the “Board”), all committees thereof and from his position as Board Chair, effective March 20, 2026. Mr. Kenny’s decision to retire was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices. The Board appointed Patricia A. Hemingway Hall, who is a current director, as Board Chair, effective immediately.

   Read the 8-K filing
3. Mar 5, 2026

   On March 2, 2026, Mary Scherer, Senior Vice President and Chief Accounting Officer, notified Cardinal Health, Inc. (the “Company”) that she intends to retire in February 2027. The Company will initiate a search process to identify her successor. Ms. Scherer will continue to serve as Chief Accounting Officer until her successor is identified and onboarded to ensure a smooth transition.

   Read the 8-K filing
4. Mar 10, 2025

   On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately. Messrs. Musslewhite and Ramakrishna will serve until the 2025 annual meeting of shareholders and until their successors are elected and qualified or until their earlier resignation, removal from office, or death. The Board has appointed Mr. Musslewhite to serve on the Audit and Human Resources and Compensation Committees and has appointed Mr. Ramakrishna to serve on the Audit and Risk Oversight Committees. Mr. Musslewhite is the former Chief Executive Officer of Definitive Healthcare Corp., a provider of healthcare commercial intelligence. Mr. Ramakrishna is the President and Chief Executive Officer of SolarWinds Corporation, a provider of observability and information technology management software.

   Read the 8-K filing
5. Sep 9, 2024

   On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders. Both Mr. Barg and Ms. Chandrasekaran will continue to serve as directors until the 2024 annual meeting of shareholders. Mr. Barg and Ms. Chandrasekaran have each indicated that their decisions are not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Both Mr. Barg and Ms. Chandrasekaran were originally appointed as members of the Board pursuant to a cooperation agreement entered into on September 5, 2022 between the Company and Elliott Associates, L.P.

   Read the 8-K filing
6. Feb 28, 2024

   On February 28, 2024, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Azelby to the Board, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation, removal from office, or death. The Board has appointed Mr. Azelby to serve on the Board's Risk Oversight Committee. Mr. Azelby is the former President and Chief Executive Officer of Eliem Therpeutics, Inc., a biotechnology company focused on developing therapies for neuronal excitability disorders. The Board has affirmatively determined that Mr. Azelby is “independent” under the rules of the New York Stock Exchange and the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Mr.

   Read the 8-K filing
7. Aug 15, 2023

   On August 10, 2023, Carrie S. Cox, a member of the Board of Directors (the “Board”) of the Company since 2009, informed the Company that she has decided not to stand for re-election to the Board when her term expires at the 2023 annual meeting of shareholders. Ms. Cox will continue to serve as a director until the 2023 annual meeting of shareholders and indicated that her resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

   Read the 8-K filing
8. Dec 19, 2022

   On December 16, 2022, the Board of Directors of Cardinal Health, Inc. (the “Company”) elected Aaron E. Alt, 51, as Chief Financial Officer (“CFO”) of the Company, effective February 10, 2023. Mr. Alt will succeed Patricia M. English, who will continue to serve as interim CFO until February 10, 2023. Mr. Alt has served as Executive Vice President and Chief Financial Officer of Sysco Corporation, a foodservice distribution company, since December 2020. Prior to that, Mr. Alt served as Senior Vice President and Chief Financial Officer of Sally Beauty Holdings, Inc., an international specialty retailer and distributor of professional beauty supplies, and President of Sally Beauty Supply from October 2018 to November 2020. Prior to that, Mr. Alt was Sally Beauty Holdings' Senior Vice President, Chief Financial Officer, and Chief Administrative Officer from May 2018 to October 2018.

   Read the 8-K filing
9. Sep 8, 2022

   On September 8, 2022, Cardinal Health, Inc. (the “Company”) announced that Victor L. Crawford will cease to serve as Chief Executive Officer, Pharmaceutical Segment effective September 19, 2022. Mr. Crawford will remain with the Company through November 13, 2022 to help with the transition of the role to his replacement. The Board of Directors of the Company has determined that Mr. Crawford’s departure from the Company will entitle him to severance benefits as an involuntary termination without cause under the Cardinal Health, Inc. Senior Executive Severance Plan (as amended, the "Severance Plan") following his departure date. Receipt of these severance benefits is subject to the terms of the Severance Plan, including the required execution of a general release and compliance with certain restrictive covenants.

   Read the 8-K filing
10. Sep 6, 2022

    below), the size of the Board will be automatically decreased to 13 directors at the conclusion of the 2022 Annual Meeting. In connection with the appointment of the New Directors, the Company also established an advisory Business Review Committee (the “Business Review Committee”) to address the matters contemplated by the Cooperation Agreement and the charter of the Business Review Committee. The Committee has three members: Jason M. Hollar, the Business Review Committee’s chair and the Chief Executive Officer of the Company, the Investor Designee and Akhil Johri. The Business Review Committee, with the assistance of the Company’s legal and financial advisors, will make recommendations to the full Board. Pursuant to the Cooperation Agreement, Elliott has agreed to abide by certain standstill restrictions and voting commitments.

    Read the 8-K filing
11. Aug 11, 2022

    Chief Executive Officer Transition On August 10, 2022, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Jason M. Hollar, 49, as Chief Executive Officer (“CEO”) of the Company, effective September 1, 2022. Mr. Hollar will succeed current CEO Michael C. Kaufmann, who will depart from the Company on September 1, 2022. The Board also elected Mr. Hollar as a director effective August 11, 2022. Mr. Kaufmann will resign as a member of the Board on September 1, 2022. Mr. Hollar has served as Chief Financial Officer (“CFO”) of the Company since May 2020. He previously served as Executive Vice President and CFO of Tenneco Inc. from July 2018 to April 2020. He was Senior Vice President Finance at Tenneco Inc. from June 2017 to June 2018 and CFO of Sears Holding Corporation from October 2016 to April 2017. In connection with Mr.

    Read the 8-K filing
12. Nov 9, 2021

    (e) On November 5, 2021, Cardinal Health, Inc. (the "Company") held its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) at which, among other things, the Company’s shareholders approved the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (the “2021 LTIP”). Under the 2021 LTIP, 25,000,000 of the Company's common shares (subject to adjustment in certain circumstances) will be available for grants of stock options, stock appreciation rights, stock awards, and other stock-based awards (as well as cash awards) to employees of the Company and its affiliates, including executive officers and non-employee directors of the Company. Under the terms of the 2021 LTIP, the aggregate number of common shares available under the plan was reduced from 25,000,000 by an aggregate of 28,700 shares, representing awards granted under the Amended Cardinal Health, Inc.

    Read the 8-K filing
13. Apr 5, 2021

    (b) On March 31, 2021, Calvin Darden notified Cardinal Health, Inc. (the “Company”) of his decision to retire from the Company’s Board of Directors, effective as of April 2, 2021. Mr. Darden’s retirement is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. 2

    Read the 8-K filing
14. Nov 9, 2020

    of Form 8-K, this Current Report on Form 8-K/A amends and supplements the information reported under

    Read the 8-K filing
15. Aug 31, 2020

    On August 30, 2020, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Sheri H. Edison to the Board, effective September 1, 2020, to serve until the 2020 annual meeting of shareholders and until her successor is elected and qualified or until her earlier resignation, removal from office or death. As of the time of this filing, the Board has not yet determined Ms. Edison’s committee service. Ms. Edison is Executive Vice President and General Counsel of Amcor plc, a global packaging company. Ms. Edison will participate in the non-management director compensation arrangements described in the Company’s definitive proxy statement for the 2019 annual meeting of shareholders filed with the Securities and Exchange Commission on September 20, 2019.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.